EATG » Hepatitis

Hepatitis

Sofosbuvir/velpatasvir/voxilaprevir improves outcomes after prior DAA regimen failure

In patients with chronic hepatitis C virus (HCV) infection who did not achieve a sustained virologic response (SVR) with a prior direct-acting antiviral (DAA) regimen, treatment with sofosbuvir/velpatasvir/voxilaprevir improves patient-reported…

Latest issue of Journal of Virus Eradication now online

The Journal of Virus Eradication provides a specialist, open-access forum and fast-track pathway to publish work in the rapidly developing field of virus eradication, particularly of HIV, HBV and HCV.…

HBV therapy nonadherence increases risk for liver-related complications

Medication nonadherence among patients with hepatitis B increased the risk for hepatocellular carcinoma, cirrhotic complications and all-cause mortality, according to recently published data. “Adherence appears to be a key factor…

Using hepatitis C-infected donor kidneys could reduce time on dialysis for transplant patients with HCV

CINCINNATI--Transplanting hepatitis C (HCV)-infected dialysis patients with organs from HCV-positive donors and then treating the infection after transplantation is more effective, costs less and will shorten wait times for donated…

Hepatitis C vaccine could dramatically reduce transmission in people who inject drugs

MAYWOOD, IL - Among the most serious consequences of the opioid epidemic is the spread of hepatitis C among injecting drug users. A major new study shows that if a…

Curbing hepatitis B in the United States will save lives and money, according to a new study

Hepatitis B used to get no play. But earlier this year, it made the headlines when scientists discovered that it’s the oldest virus known to affect humans — at least…

Assembly Biosciences initiates two Phase 2a trials of ABI-H0731 for the treatment of hepatitis B

Key aim is to demonstrate that core inhibitor therapy combined with standard of care antivirals can offer curative potential for HBV INDIANAPOLIS and SAN FRANCISCO, July 09, 2018 -- Assembly Biosciences, Inc. (Nasdaq:ASMB), today…

HBV antibody levels after NA discontinuation predict relapse risk

Discontinuation of nucleos(t)ide analogue therapy for chronic hepatitis B correlated with risk for clinical relapse based on total serum level of HBV core antibodies after 2.5 years of follow-up, according…

DAA HCV therapy possible in successfully treated hepatocellular carcinoma

The treatment of hepatitis C virus (HCV) infection is possible in patients who have been successfully treated for hepatocellular carcinoma (HCC), and the best results were achieved with the use of multiple…

ECDC: Hepatitis B – Annual epidemiological report for 2016

The European Centre for Disease Prevention and Control (ECDC) released the Hepatitis B – Annual epidemiological report for 2016. The report can be downloaded here.

1 2 3 82